Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Biotech
Exelixis’ Cabometyx successor misses primary endpoint in CRC trial
While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.
Angus Liu
Jun 22, 2026 3:40pm
A 5-month sprint: Inside Pfizer's $10B deal with Innovent
Jun 21, 2026 10:41pm
3 Genentech VPs among those dismissed in latest layoff round
Jun 11, 2026 2:30pm
Roche garners EU approval on label expansions for dx platform
Jun 11, 2026 9:02am
Roche sticks with €600M diagnostics investment in Germany
Jun 9, 2026 8:00am
Fierce Pharma
Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says
Jun 8, 2026 3:12pm
